Canada approves Moderna's RSV vaccine for adults aged 60 and older
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
Inside Moderna’s Tech-Driven Culture: Insights From CIO Brad Miller
Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...
AOL16h
The Oncology Bet Is Already Paying Off For Pfizer
On the other hand, Moderna Inc (NASDAQ: MRNA) posted a surprise profit and higher than expected revenue following the launch ...
How Moderna used niche influencers to drive vaccinations despite COVID fatigue
Coegi used more than 500 million impressions and paid social optimized with attention and emotion metrics to drive 24% of ...
Moderna sales get lift from early nod for newest COVID shot
The Cambridge-based company’s latest COVID shot was approved three weeks earlier than last year, according to a statement ...
Moderna Tops BioSpace's Best Places to Work Ranking for Fourth Consecutive Year
CAMBRIDGE, MA / ACCESSWIRE / November 12, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked the number one large employer in ...
BioPharma Dive6d
Moderna earnings beat forecasts, but analysts question whether sales spike will last
Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.
Canada approves Moderna's RSV vaccine for those age 60 and older, company says
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn
Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...
Cautious Outlook on Moderna: Declining Vaccine Demand and Strategic Challenges Prompt Sell Rating
Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...
Pfizer, GSK, Moderna struggle in a shrinking RSV vaccine market
Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...
Moderna Stock Rises on Surprise Q3 Profit
Moderna reported better third-quarter results than expected Thursday morning, as the vaccine maker reported a surprise profit for the period amid its efforts to cut costs and $1.8 billion in sales of ...